CPA3 and melanoma: Even when binding of a protein to serum antibodies is confirmed by Western blot, as was the case with the CPA3 protein and the melanoma patient’s serum antibodies, this binding does not necessary mean that the immune response was directed against this protein, but could be attributed to the cross reactivity.